Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Ceribell Inc. launched its initial public offering of more than 10.6 million shares of common stock at $17 and steadily saw ...

To recreate in the laboratory the formation of Lewy bodies as they would occur in a Parkinson’s patient, two ingredients are required: the protein α-synuclein and the participation of the immune ...

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance ...

Clostridioides difficile is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and ...

Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular ...

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to ...

Glooko Inc. secured a $100 million series F financing to support expansion of its diabetes ecosystem platform, which ...

Duchenne muscular dystrophy is a severe and progressive disorder caused by mutations in the dystrophin (DMD) gene that lead ...

Ligachem Bioscience Inc., of Daejeon, South Korea, and Osaka, Japan-based Ono Pharmaceutical Co. Ltd. agreed to two antibody-drug conjugate (ADC) deals that could reach $700 million (₩943.5 billion) ...

Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long ...

Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the ...